CUE stock forecast, quote, news & analysis
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders... Show more
Why Cue Biopharma (CUE) Stock Is Down -13.2% in the Last 30 Days
Key Takeaways
- Cue Biopharma (CUE) shares declined roughly 13.2% over the trailing 30 days, falling from a closing price of $30.50 on September 9, 2026, to an intraday price near $26.48 in early October.
- The decline followed a sharp mid-September run-up that briefly pushed the stock above $41 before a high-volume reversal erased the gains.
- Over the broader three-month period, the stock is down approximately 27%, reflecting persistent volatility and a challenging backdrop for clinical-stage biotechs.
- Key influences include the company's transition toward its lead allergy and autoimmune programs, ongoing cash-runway considerations, and the inherently binary nature of early-stage drug development.
- Upcoming clinical and regulatory milestones, along with financing and dilution dynamics, are likely to remain the primary drivers of near-term price action.
Cue Biopharma (CUE) Company Overview and Market Position
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts. The company develops injectable biologics designed to selectively engage and modulate disease-specific T cells, using its proprietary Immuno-STAT platform to target disease mechanisms without broad systemic immune suppression. Its lead asset, CUE-221, is a novel anti-IgE antibody with a dual mechanism of action in Phase 2 development for allergic diseases, while CUE-401, a bifunctional IL-2 and TGF-β program, is advancing toward Phase 1 development for autoimmune and inflammatory conditions. As a small, development-stage company with a limited product pipeline and no marketed therapies, Cue Biopharma is followed primarily by investors focused on clinical catalysts, partnership economics, and balance-sheet durability.
Cue Biopharma (CUE) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, CUE shares have moved sharply lower on a net basis. The stock closed at $30.50 on September 9, 2026, and traded near $26.48 in early October, a decline of approximately 13.2%. This net move masks substantial intraday swings: the stock surged above $41 in mid-September before reversing in a single high-volume session that saw shares fall from the $38 range toward the mid-$20s.
The picture is more pronounced over the trailing three-month period. From a closing level of $36.51 on July 9, 2026, the stock has declined roughly 27%, trading in an exceptionally wide range that included an intraday peak near $45.50 in early July and a retreat toward the low-$20s by early October. This sustained volatility underscores the speculative, catalyst-driven nature of the stock.
What Drove CUE Stock Price in the Last 30 Days
The most visible feature of the past month has been extreme price volatility rather than a single, linear trend. After a pronounced run-up in mid-September, shares underwent a rapid reversal characterized by unusually heavy trading volume and intraday ranges spanning double-digit percentages. Such moves are common in thinly traded, clinical-stage biotechnology companies, where limited float can amplify price swings and where news-driven repositioning occurs quickly.
Broader company-specific factors also contributed to sentiment. Cue Biopharma remains in the midst of a strategic transformation centered on its CUE-221 allergy program and CUE-401 autoimmune candidate, and its financial position continues to command investor attention. The company reported $17.4 million in cash and equivalents as of June 30, 2026, with a $50 million private placement completed shortly thereafter. For a company without approved products, questions around cash runway and the potential for future dilution can weigh on the stock between clinical readouts. The recent decline reflects a combination of profit-taking after a sharp rally, ongoing balance-sheet considerations, and reduced risk appetite within the small-cap biotech segment.
What Drove CUE Stock Performance Over the Last Quarter
The three-month trend has been defined by an overall downward drift punctuated by sharp, short-lived spikes. The company's second-quarter 2026 results highlighted the financial impact of its strategic realignment, including a net loss of $153.1 million driven largely by one-time, non-cash charges tied to a license agreement, alongside elevated operating expenses related to the company's transformation. The subsequent $50 million private placement provided additional capital but also introduced dilution considerations that have influenced investor sentiment.
At a strategic level, Cue Biopharma has consolidated its focus on its most advanced assets while pursuing collaborations and partnerships to support development. This repositioning—combined with the reality that the company's valuation remains tied to future clinical outcomes rather than current revenue—has kept the stock highly sensitive to headline risk. Over the quarter, the absence of major positive clinical catalysts to offset financing and execution concerns contributed to the net decline.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots drawn from a broader universe of hundreds of bots that trade across thousands of tickers. Only the top-performing and most relevant bots are featured in this section, giving users a focused view of strategies currently demonstrating strength in the market. These bots vary widely in strategy, timeframe, and performance metrics, allowing traders to explore approaches aligned with their own objectives and risk tolerance. For investors and traders looking to complement their own research with data-driven, automated signals, the Trending AI Robots page offers a practical starting point for discovering current market leaders.
CUE Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor several factors that are likely to shape Cue Biopharma's stock going forward. Clinical progress remains paramount: Phase 2 data for CUE-221 and the initiation of the CUE-401 Phase 1 study represent the most significant value-creating milestones. Regulatory and development timelines, along with any partnership or collaboration announcements, will also be closely watched given the company's reliance on strategic alliances to advance and fund its pipeline.
Financial execution is equally important. Updates on cash position, operating expenses, and any additional financing activity will inform assessments of dilution risk and runway. Finally, broader market conditions—including risk appetite for speculative biotech names, sector-wide capital flows, and interest-rate dynamics—may continue to influence the stock's volatility. These considerations are informational in nature and do not constitute investment advice.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for CUE turns negative, indicating new downward trend
CUE saw its Momentum Indicator move below the 0 level on September 28, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 95 similar instances where the indicator turned negative. In 90 of the 95 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for CUE turned negative on September 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 48 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
CUE moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CUE crossed bearishly below the 50-day moving average on October 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CUE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
CUE broke above its upper Bollinger Band on September 16, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CUE entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CUE's RSI Oscillator exited the oversold zone, 36 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +17.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where CUE advanced for three days, in 185 of 231 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. CUE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CUE's P/B Ratio (59.593) is slightly higher than the industry average of (2.988). P/E Ratio (-0.643) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (4.143) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CUE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of biopharmaceuticals
Industry Biotechnology